200M Fund and Seventure Partners invest together a total of €2,5M in LiMM Therapeutics, a biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues, bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

By decoding the language of the neuroimmune cross-talk, LiMM is developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory, infectious and metabolic diseases.

Marco Fernandes, CEO of PME Investimentos, points out that “it is the first time that a life sciences technology developed at a portuguese university is able to attract international venture capital as specialized as Seventure Partners. 200M Fund is honored to support the entrepreneurs and scientific researchers from the Champalimaud Foundation, Henrique Veiga Fernandes and David Braga Malta and the future development of LiMM.”

 

Share This Post: